CA2478237C — Use of adapalene for the treatment of dermatological disorders
Assigned to Galderma Research and Development SNC · Expires 2009-05-12 · 17y expired
What this patent protects
The present invention relates to the use of 6-[3-(1-adamantyl)-4-methoxypheny]-2-naphthanoic acid (adapalene), or of its salts, for producing a pharmaceutical composition intended for the treatment of dermatological elements with an inflammatory or proliferative component, compri…
USPTO Abstract
The present invention relates to the use of 6-[3-(1-adamantyl)-4-methoxypheny]-2-naphthanoic acid (adapalene), or of its salts, for producing a pharmaceutical composition intended for the treatment of dermatological elements with an inflammatory or proliferative component, comprising 0.3% by weight of adapalene relative to the total weight of the composition.
Drugs covered by this patent
- Differin (ADAPALENE) · Galderma Labs Lp
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.